Sunny Sharma
Senior Managing Director @ OrbiMed
Mumbai, India
Sunny Sharma is a venture - series unknown investor at OrbiMed in Mumbai focused on Health Care and Medical. Sunny Sharma is based out of Mumbai, Maharashtra and is the Senior Managing Director of OrbiMed and also serves as a Board Member for Pee Safe. Sunny previously worked at Investor Growth Capital Limited as a Venture Partner and Vice President. Sunny Sharma attended the Christian Medical College & Hospital.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Sunny Sharma invests in
Stages Sunny Sharma invests in
Countries Sunny Sharma invests in
Investment Focus
Industry
- Health Care 7 (70%)
- Medical 3 (30%)
- Biotechnology 3 (30%)
- E-Commerce 2 (20%)
- Pharmaceutical 2 (20%)
Stage
- Venture - Series Unknown 3 (30%)
- Series C 2 (20%)
- Private Equity 2 (20%)
- Series A 1 (10%)
- Series B 1 (10%)
Country
- India 7 (70%)
- United States 2 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Iswarya Fertility Center
|
Iswarya Fertility Center provides IVF, IUI, egg donation, azoospermia, ovulation induction, and miscarriage treatment solutions. | $37M / Private Equity / Jul 09, 2026 | |
TruNativ
|
Trunative is a producer and distributor of nutrition products under the TruNativ brand targetting health and fitness enthusiasts. | $30M / Series B / Jun 16, 2026 | |
Pee Safe
|
Pee Safe was started in 2013, launching the first of its kind toilet seat sanitizer. Since 2017, the company has expanded into several personal hygiene categories including feminine hygiene (pads, tampons, cups, etc), men's intimate hygiene, hand hygiene (Palm Safe), face mask and mist (Pollution Safe), while being one of the leaders in a fewsub-categories. | $32M / Series C / Jan 14, 2026 | |
Arcatron Mobility
|
Arcatron Mobility is a medical device startup focused on designing and selling innovative products to enhance lives of people with limited mobility. Arcatron was founded by four engineers of NIT Calicut in June 2015 with a moto of Purpose Driven Innovation.The company has a focus on India’s 1/3rd of 110 million+ elderly citizens needingassistance in carrying out activities of Daily Living (ADL’s) like bathing, toileting, walking. Demand for mobility assistance is increasing due to the rapid rate of aging, spinal cord injuries and obesity. However, the mobility devices available in India are poor quality or unaffordable. Arcatron aims to fix this problem by building world-class mobility devices at affordable prices.Arcatron Mobility has a vision to become domestic market leader in most competing categories and one of the world’s most trusted medical device brands by 2022. | Venture - Series Unknown / Feb 15, 2024 | |
Innvolution Healthcare
|
Innvolution Med System is a company that operates in the medical device industry. The company was established by a group of leaders with extensive experience in the cardiovascular sector. Innvolution Med System's primary focus is on developing and providing innovative solutions for cardiovascular health. The company's offerings include arange of medical devices and technologies designed to improve patient outcomes and enhance the quality of care in the cardiovascular field. | Private Equity / Apr 10, 2023 | |
|
LifeWell
|
LifeWell is a new entity formed through the merger of LifeCell’s diagnostics business and MFine. | $80M / Venture - Series Unknown / Jul 11, 2022 | |
LifeCell International
|
LifeCell is a private stem cell bank that brings the concept of umbilical cord stem cell banking to India.Set up in the year 2004, LifeCell started out as an umbilical cord stem cell banking company and has now grown to become a comprehensive stem cells solutions provider with a complete spectrum of services including multi-service stem cellbanking, R&D, stem cell clinical trials, and stem cell therapy. Based in Chennai, LifeCell has a spread over 100 service centers in India and the GCC countries. | $34.6M / Venture - Series Unknown / Sep 21, 2021 | |
Morphotek
|
Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continuesto develop additional antibody products using its proprietary technologies.Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets. | $40M / Series D / Oct 12, 2006 | |
TransMolecular
|
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technologyplatforms to enrich its product discovery and development pipeline.Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms.The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama.TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively. | $33.2M / Series C / Mar 01, 2004 | |
Netmeds
|
Who we are - India's most convenient online pharmacyNetmeds.com, India Ki Pharmacy, is brought to you by the Dadha & Company – one of India’s most trusted pharmacies, with over 100 years’ experience in dispensing quality medicines. At netmeds.com, we help you look after your own health effortlessly as well as take care of loved oneswherever they may reside in India. You can buy and send medicines from any corner of the country - with just a few clicks of the mouse. | $50M / Series A |
Co-Investors
Aperture Venture Partners
1 deal together
CB Health Ventures
1 deal together
Diamond Capital Management
1 deal together
About OrbiMed
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investmentsseries of venture capital funds and a family of public equity investment funds.
OrbiMed Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dina Chaya
Partner
|
|||
Kevin Koch
Venture Partner
|
|||
Rishi Gupta
Private Equity Partner
|
|||
|
Sunny Sharma
Senior Managing Director
|
|||
Tadd S. Wessel
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sunny Sharma invest in?
Sunny Sharma invests primarily in Health Care, Medical and Biotechnology startups, most often at Venture - Series Unknown and Series C stage. Most of the 10 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Sunny Sharma last invest?
The most recent investment recorded for Sunny Sharma closed in Jul 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
